These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2793413

  • 21. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [Abstract] [Full Text] [Related]

  • 22. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
    Graham JS, Henderson JM, Morris JG, Yiannikas C.
    Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
    Pacchetti C, Martignoni E, Sibilla L, Bruggi P, Turla M, Nappi G.
    Eur Neurol; 1990 Feb; 30(6):319-23. PubMed ID: 2289507
    [Abstract] [Full Text] [Related]

  • 24. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ.
    Eur Neurol; 1987 Feb; 27 Suppl 1():126-34. PubMed ID: 3428306
    [Abstract] [Full Text] [Related]

  • 25. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [Abstract] [Full Text] [Related]

  • 29. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS, Covicković-Sternić N.
    Neurologija; 1990 Dec; 39(2):99-105. PubMed ID: 2267052
    [Abstract] [Full Text] [Related]

  • 30. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Eur Neurol; 1987 Dec; 27 Suppl 1():114-9. PubMed ID: 3322835
    [Abstract] [Full Text] [Related]

  • 31. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
    Kleedorfer B, Poewe W.
    J Neural Transm Park Dis Dement Sect; 1992 Dec; 4(2):173-8. PubMed ID: 1571080
    [Abstract] [Full Text] [Related]

  • 32. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA.
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI, Sadekov RA, Golubev VL.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000 Mar; 100(12):46-8. PubMed ID: 11195538
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P, Rondot P, Taberlet A, Baumann N.
    Biomedicine; 1974 Dec 10; 21(12):486-90. PubMed ID: 4462871
    [No Abstract] [Full Text] [Related]

  • 40. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA, Celano I, Parati E, Girotti F.
    J Neurol Neurosurg Psychiatry; 1977 Dec 10; 40(12):1142-6. PubMed ID: 591982
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.